Executives at Novavax have said the company’s manufacturing capacity can meet the demand in the US for a COVID-19 vaccine in 2021.
At the peak, Novavax expects demand in the US to hit as many as 500 million to 600 million doses per year. The company plans to start producing its vaccine candidate NVX-CoV2372 on a large scale at the beginning half of 2021, and expects to manufacture over two billion doses of the vaccine annually if it proves effective in late-stage trials.
Last week, Novavax posted positive results from a phase 1 trial of NVX-CoV2373, in which the candidate was evaluated at two dose levels – 5µg and 25µg – with and without an adjuvant in 131 healthy adults between the ages of 18 and 59 years.
In the early study, the vaccine produced high levels of antibodies against the SARS-CoV-2 virus, which causes COVID-19, following a single dose. Participants also demonstrated higher levels of antibodies after two doses compared to the levels seen in recovered COVID-19 patients.
Read more: http://www.pmlive.com/pharma_news/novavax_plans_to_meet_us_covid-19_vaccine_demand_in_2021_1346743